PositiveID

PositiveID is a life sciences company that specialized in biological detection systems and diagnostic solutions for the healthcare and homeland security markets. The company's flagship technology, Firefly Dx, was developed as a handheld, point-of-care molecular diagnostic platform designed to provide rapid DNA and RNA detection for clinical and environmental applications. In addition to diagnostics, PositiveID provided diabetes management tools and was historically known for its implantable RFID microchip technology for patient identification. While the company was a pioneer in mobile molecular diagnostics, it faced significant financial challenges and its SEC registration was revoked in 2021. Its portfolio aimed to address critical needs in infectious disease testing and real-time pathogen monitoring.